PHC Corporation has signed a Master Collaboration Agreement with CCRM to work together on the development of primary T-cell(*1) expansion culture processes that will seek to accelerate the manufacturing of cell and gene therapy (CGT) products. This joint initiative will integrate
PHC
The Biomedical Division of PHC Corporation (Headquarters: Chiyoda-ku, Tokyo, Japan; President: Nobuaki Nakamura), has received a 2024 Innovation Award from The Analytical Scientist1 for its live cell metabolic analyzer, LiCellMoTM. LiCellMo, launched for research use in Japan in September and the United States, UK, EU, China and other Asian select geographies in
PHC Corporation Biomedical Division (headquarters: Chiyoda-ku, Tokyo, President: Nobuaki Nakamura; hereafter Biomedical Division) announced today the commercial launch of LiCellMo, a live cell metabolic analyzer that allows researchers to visualize metabolic(*1) changes in cell cultures, providing a more complete picture of cell activity for research uses in cell